Heraeus Medical Components 09.06.19
Heraeus Medical Components, a global business unit of Heraeus Holding GmbH, has finalized an agreement to acquire Via Biomedical. Via Biomedical is a leading outsourcing partner for medical device OEM companies focused on contract development, prototyping, processing, and manufacturing of interventional devices. This investment expands Heraeus’ existing capabilities within growing interventional device markets and is the third technology acquisition in the past 24 months.
Founded in 2001, Via Biomedical has core development competencies in catheters, balloons, stent delivery systems, molded medical device products, and assemblies regularly used in interventional cardiology, neurovascular, and peripheral vascular markets. “The acquisition of Via Biomedical is part of our continued investment to support our medical device customers in the vascular field,” said Nicolas Guggenheim, president of Heraeus Medical Components.
David Ohmann, executive VP, Interventional Solutions at Heraeus added, “Via Biomedical has an impressive track record with their engineering agility. When you combine their strengths with our global reach and excellence in high-volume manufacturing, OEM medical device customers will be able to shorten development cycles and get innovative products to market faster.”
Founded in 2001, Via Biomedical has core development competencies in catheters, balloons, stent delivery systems, molded medical device products, and assemblies regularly used in interventional cardiology, neurovascular, and peripheral vascular markets. “The acquisition of Via Biomedical is part of our continued investment to support our medical device customers in the vascular field,” said Nicolas Guggenheim, president of Heraeus Medical Components.
David Ohmann, executive VP, Interventional Solutions at Heraeus added, “Via Biomedical has an impressive track record with their engineering agility. When you combine their strengths with our global reach and excellence in high-volume manufacturing, OEM medical device customers will be able to shorten development cycles and get innovative products to market faster.”
